Current characteristics associated with hereditary angioedema attacks and treatment: The home infusion based patient experience

被引:11
|
作者
Tachdjian, Raffi [1 ]
Banerji, Aleena [2 ]
Guyer, Autumn [2 ]
Morphew, Tricia [3 ]
机构
[1] Univ Calif Los Angeles, Los Angeles, CA USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Morphew Consulting LLC, Los Angeles, CA USA
关键词
C1 INHIBITOR DEFICIENCY; QUALITY-OF-LIFE; ECALLANTIDE TREATMENT; THERAPY; UPDATE; MANAGEMENT; BURDEN; RECOMMENDATIONS; EPIDEMIOLOGY; DEPRESSION;
D O I
10.2500/aap.2015.36.3832
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
This article presents a current perspective on the characteristics of hereditary angioedema (HAE) attacks and treatment as captured by a home infusion service. Retrospective data on 158 HAP patients who were enrolled in this acute treatment program were analyzed for factors surrounding an attack. The majority of patients had a high level of disease severity at baseline (88%), with a higher than expected likelihood of having a positive family history (87.8%). The most likely times for patients to call for home treatment were just before and during working hours (6:00 A.M.-5:00 P.M.). Eighty-three percent had more than one alternate mode of medication. Factors associated with a severe attack included an overall severe rating of HAP attacks in the previous year, an abdominal attack alone or a combination of peripheral and abdominal attacks versus a peripheral attack alone, and the use of two doses rather than one for treatment of the current attack. Average time to relief onset was 43.5 minutes. One dose of ecallantide was sufficient to treat the majority of attacks, and a second dose was needed in 23.6% of patients experiencing a severe attack. However, patients who reported both a severe attack rating during the previous year and experiencing only a peripheral current attack were more likely to experience a severe current attack. Acute treatment paradigms for HAP remain diverse. Understanding factors driving these decisions could help alleviate the overall burden of this disease and help overcome some of the challenges faced by the patients and their caretakers and improve their quality of life. Enhanced capture and analysis of prodromal factors in future studies should help us further alleviate the burden of this disease.
引用
收藏
页码:151 / 159
页数:9
相关论文
共 50 条
  • [21] Treatment of Hereditary Angioedema Attacks with Icatibant and Recombinant C1 Inhibitor During Pregnancy
    Hakl, Roman
    Kuklinek, Pavel
    Krcmova, Irena
    Kralickova, Pavlina
    Freiberger, Tomas
    Janku, Petr
    Vlkova, Marcela
    Litzman, Jiri
    JOURNAL OF CLINICAL IMMUNOLOGY, 2018, 38 (07) : 810 - 815
  • [22] Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children
    Reshef, Avner
    Grivcheva-Panovska, Vesna
    Kessel, Aharon
    Kivity, Shmuel
    Klimaszewska-Rembiasz, Maria
    Moldovan, Dumitru
    Farkas, Henriette
    Gutova, Vaclava
    Fritz, Stephen
    Relan, Anurag
    Giannetti, Bruno
    Magerl, Markus
    PEDIATRIC ALLERGY AND IMMUNOLOGY, 2019, 30 (05) : 562 - 568
  • [23] Factors associated with hospital admission in hereditary angioedema attacks: a multicenter prospective study
    Javaud, Nicolas
    Gompel, Anne
    Bouillet, Laurence
    Boccon-Gibod, Isabelle
    Cantin, Delphine
    Smaiti, Nadia
    Carpentier, Francoise
    Boubaya, Marouane
    Launay, David
    Adnet, Frederic
    Fain, Olivier
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2015, 114 (06) : 499 - 503
  • [24] Variability of prodromal signs and symptoms associated with hereditary angioedema attacks: A literature review
    Kemp, John G.
    Craig, Timothy J.
    ALLERGY AND ASTHMA PROCEEDINGS, 2009, 30 (05) : 493 - 499
  • [25] Recombinant Human C1 Inhibitor (Conestat Alfa) In the Treatment of Angioedema Attacks in Hereditary Angioedema
    Plosker, Greg L.
    BIODRUGS, 2012, 26 (05) : 315 - 323
  • [26] Assessment of rebound and relapse following ecallantide treatment for acute attacks of hereditary angioedema
    Bernstein, J. A.
    Shea, E. P.
    Koester, J.
    Iarrobino, R.
    Pullman, W. E.
    ALLERGY, 2012, 67 (09) : 1173 - 1180
  • [27] Modeling Cost-Effectiveness of On-Demand Treatment for Hereditary Angioedema Attacks
    Bernstein, Jonathan A.
    Tyson, Christopher
    Relan, Anurag
    Adams, Philippe
    Magar, Raf
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (02) : 203 - +
  • [28] Paediatric hereditary angioedema: a survey of UK service provision and patient experience
    Read, N.
    Lim, E.
    Tarzi, M. D.
    Hildick-Smith, P.
    Burns, S.
    Fidler, K. J.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2014, 178 (03) : 483 - 488
  • [29] Attack frequency and associated factors in hereditary angioedema patients: a single-centre experience
    Durmaz, Makbule Seda Bayrak
    Sevimli, Nurgul
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2025, 42 (01): : 75 - 82
  • [30] The adolescent experience of hereditary angioedema: a qualitative study of disease burden and treatment experience
    Broderick, Lynne
    Foster, April
    Waldman, Laura Tesler
    Bordone, Laura
    Yarlas, Aaron
    ORPHANET JOURNAL OF RARE DISEASES, 2025, 20 (01)